SKYHAWK THERAPEUTICS, INC. – Trademark Portfolio
Entity Type: 03
SKYHAWK THERAPEUTICS, INC. holds 20 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 13 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 10 trademarks are registered and 7 are pending. Notable registered marks include SKYAI, SKYSEQ, SKYHAWK, SKYSTAR, and SKYLIBRARY. The owner is based in Waltham, MA.
35 Gatehouse Drive
Waltham, MA 02451
Showing of trademarks Trademarks
Trademark Classifications
SKYHAWK THERAPEUTICS, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does SKYHAWK THERAPEUTICS, INC. have?
SKYHAWK THERAPEUTICS, INC. has 20 U.S. trademarks filed with the USPTO. Of these, 10 registered, 7 pending, 3 abandoned.
What trademark classes does SKYHAWK THERAPEUTICS, INC. file in?
SKYHAWK THERAPEUTICS, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are SKYHAWK THERAPEUTICS, INC.'s most well-known trademarks?
SKYHAWK THERAPEUTICS, INC.'s registered trademark portfolio includes well-known marks such as SKYAI, SKYSEQ, SKYHAWK, SKYSTAR, and SKYLIBRARY. These are among 10 currently registered trademarks in the portfolio.
What is SKYHAWK THERAPEUTICS, INC.'s trademark registration success rate?
SKYHAWK THERAPEUTICS, INC. has a 77% trademark registration rate, with 10 out of 13 resolved applications resulting in successful registration. Currently, 7 applications are pending review.